Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007171 | 0.91 | NTRK1 (0.44) | NTRK1GPR17DYRK1AMAP2K4MAP2K7 | |
| SCHEMBL4014693 | 0.86 | NTRK1 (0.48) | NTRK1GPR17P2RY2DYRK1A | |
| SCHEMBL4013332 | 0.85 | GPR17 (0.40) | NTRK1GPR17P2RY2KMT2AMAP2K4 | |
| SCHEMBL4013301 | 0.84 | FLT3 (0.51) | GPR17P2RY2KMT2ADYRK1AWNT1 | |
| SCHEMBL4013454 | 0.82 | GPR17 (0.37) | GPR17P2RY2MAP2K4MAP2K7 | |
| SCHEMBL4010010 | 0.82 | GPR17 (0.37) | GPR17P2RY2MAP2K4MAP2K7 | |
| SCHEMBL4009643 | 0.82 | TDP1 (0.38) | GPR17P2RY2MAP2K4MAP2K7 | |
| SCHEMBL4008733 | 0.81 | APEX1 (0.46) | NTRK1BRAFCSNK2A1PRKAG1PRKAA1 | |
| SCHEMBL4010904 | 0.80 | MAP2K4 (0.47) | DYRK1AMAP2K4MAP2K7CDK2PRKD3 | |
| SCHEMBL4009669 | 0.79 | NTRK1 (0.41) | NTRK1GPR17P2RY2MAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1342/4885GPR17 2871/4885P2RY2 1388/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1376/4885GPR17 2968/4885P2RY2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.